Keros Therapeutics Inc
NASDAQ:KROS
Earnings Announcements
Keros Therapeutics Reports First Quarter 2022 Financial Results
Published: 05/05/2022 12:48 GMT
Keros Therapeutics Inc (KROS) - Keros Therapeutics Reports First Quarter 2022 Financial Results.
Keros Therapeutics Inc - Expects Cash It Had on Hand at March 31, 2022 Will Fund Operating Expenses and Capital Expenditure Requirements Into Q1 of 2024.
Keros Therapeutics Inc - Qtrly Loss per Share $1.01.
Keros Therapeutics Inc - Expects Cash It Had on Hand at March 31, 2022 Will Fund Operating Expenses and Capital Expenditure Requirements Into Q1 of 2024.
Keros Therapeutics Inc - Qtrly Loss per Share $1.01.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.07
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.14
More details on our Analysts Page.
Adjusted EPS is expected to be -$1.07
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.14
More details on our Analysts Page.